References
1. MedlinePlus. Skin Pigmentation Disorders. 2. Al-Qarqaz F et al. Dermatology Reports. 2021;13:8223. 3. Basit H, Godse KV, Al Aboud AM. Melasma. 2022. 4. Wu Y et al. J Cosmet Dermatol. 2020;19(7):1627–1635. 5. Qian W et al. J Cosmet Dermatol. 2018;17(4):596–599. 6. Williams S et al. J Cosmet Dermatol. 2009;8(3):216–225. 7. Ribé A et al. J Cosmet Laser Ther. 2011;13(4):154–161. 8. Lee BM et al. Arch Plast Surg. 2015;42(3):282–287. 9. Lim H-K et al. J Cosmet Laser Ther. 2014;16(1):32–36. 10. Kim J. Arch Aesthetic Plast Surg. 2014;20(2):97–103. 11. Gubanova EI et al. Poster presented at IMCAS, Jan–Feb 2015, Paris, France. 12. Gubanova EI et al. J Drugs Dermatol. 2015;14(3):288–299. 13. Kerscher M et al. Dermatol Surg. 2008;34(5):720–726. 14. Dierickx C et al. Dermatol Surg. 2018;44 Suppl 1:S10–S18. 15. Gubanova EI et al. Aesthetic Med. 2010;1:94–98. 16. Belmontesi M et al. J Drugs Dermatol. 2018;17(1):83–88. 17. Data on File. MA-54615. Restylane SKINBOOSTERS Competitor Comparison. Benching document 2022. 18. Restylane® Skinboosters™ VITAL EU IFU. 2020. 19. Restylane® Skinboosters™ VITAL LIGHT EU IFU.* In a 15-month randomized, multicenter, evaluator-blinded, split-hand, no treatment-controlled study, 100 Chinese patients received treatment with Restylane® SKINBOOSTERS™ VITAL to treat one dorsal hand. During the study period, three treatments were administered in the same hand starting with initial treatment and then spaced 1 month apart.4† 80.6%; compared with before having treatment with Restylane® SKINBOOSTERS™ VITAL, as assessed by Subject Satisfaction Questionnaire. 100 patients formed the intent-to-treat population. N=total sample number.4‡ In single-center, prospective, randomized, split-face, clinical study, 10 Korean patients received intradermal injection of Restylane® SKINBOOSTERS™ VITAL in the nasojugal groove. Treatment was given in 1 session. Assessments were performed before, immediately after, and at all follow-up visits. The effect of skin tone correction was assessed by spectrophotometer and mexameter at every visit. Peak correction was observed at 4-week follow-up.5